CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)

N/A

Report date: 2022/06/30 15:18:51

Base Information

Drug NameCD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionT lymphocyte replacementsAnti-CD70Anti-CD19
TargetsProstate-Specific Membrane AntigenCD70 antigenB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Geno-Immune Medical Institute
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Geno-Immune Medical Institute
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A